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Presently, scientific knowledge on the association between urinary lead concentration and renal profile is 
limited, especially on the characteristic of urinary lead that could aggravate existing kidney disease. This 
study aims to determine the concentration of urinary lead with serum creatinine and blood urea nitrogen in 
chronic kidney disease patients and to identify the influences of confounding factors and the blood pressure 
on the chronic kidney disease patients. Graphite Furnace Atomic Absorption Spectrometer was used to 
determine the urinary lead concentration. The differences and correlation of urinary lead with serum 
creatinine, blood urea nitrogen and diastolic blood pressure between the chronic kidney disease patients and 
control groups were assessed using Mann Whitney U and Spearman correlation tests. Our findings indicated 
a significantly higher urinary lead concentration in the chronic kidney disease group compared to the control 
group (p-=0.002). Nevertheless, there is a weak relationship between urinary lead with serum creatinine, 
blood urea nitrogen and diastolic blood pressure in the chronic kidney disease group (r values: -0.123, 0.101, 
and 0.127). In addition, sociodemographic factors did not influence the concentration of urinary lead 
(p>0.05). The urinary lead concentration in the chronic kidney disease group is not substantial, thus the 
evidence of urinary lead accumulation in chronic kidney disease group who have yet to start renal 
replacement therapy is inconclusive.  
KEYWORDS 
blood urea nitrogen, chronic kidney disease, diastolic blood pressure, serum creatinine, urinary lead.
1. INTRODUCTION 
Pb (lead) is a mixture of 4 stable isotopes, 208Pb (51-53%), 206Pb (23.5- 
-27%), 207Pb (20.5-23%), and 204Pb (1.35-1.5%) that were formed vary 
by ores or rocks and naturally occurring elemental within the earth's crust 
(Cao et al., 2015). Due to its properties, Pb has become a common metal 
used in pipes, welding and storage batteries where demand is high in 
many industries. As a result of its extensive usage, it has been discovered 
that the concentration of Pb in the environment is essentially relatively 
high in many cities in developing and developed countries (Osman et al., 
2005). 
In Sabah, Pb contamination has been reported before in which the soil and 
crops in Ranau were found to have exceeded the permissible Pb level. Most 
probably the contamination originated from the abandoned copper 
mining site in the surrounding areas. Moreover, the geological area in 
Ranau is known to be rich in mineral elements compared to other places 
in Sabah, thus the Pb contamination could have also come from natural 
contamination from the geological material in the soil which contained Pb 
content (Abdul Aziz et al., 2015). This is evidenced by a study which 
reported that the concentrations of Pb in the paddy soil and rice grains in 
Papar exceeded the permissible limits for human consumption in rice 
grains by FAO/WHO (2002) (Payus et al., 2015; FAO/WHO, 2002). Rice 
grains are the main source of food intake for the local population. In 
addition, the contamination could have also originated from the busy 
transportation activities surrounding the main roads of the oil and gas 
industrial areas near Kimanis. 
At present, in most countries, these metals are already known as a toxic 
element in the human body, particularly if they reach the level of action 
(Karrari et al., 2012). Evidence has also shown that chronic exposure to 
Pb, even in a small but significant amount, can cause chronic kidney 
disease owing to Pb nephropathy. Information on U-Pb toxicity and its 
adverse effects is important for the understanding of Pb nephropathy in 
the identification of outcomes for patients with early stage of kidney 
disease. The small amount of Pb that leaves in urine every day can act as a 
positive sign and make it available for study. Previous research has shown 
that long-term exposure to Pb may represent significant toxicity and Pb 
nephropathy, which is manifested as gradually progressive interstitial 
nephritis (Evans and Elinder, 2011; Subha et al., 2012). Associations have 
also previously been recorded between increased SCr and higher levels of 
Pb (Weaver et al., 2003). In connection with this claim, also concluded that 
there is a significant association between the renal outcome and the U-Pb 
(Buser et al., 2015). Therefore, the compromised renal function in the CKD 
group can be an explanation of the accumulation of Pb in the body which 
resulted in an increased level of Pb in the urinary excretion and could 
increase the risk of their existing kidney disease (Orr and Bridges, 2017). 
However, the relationship between the U-Pb concentration in CKD 
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patients and its effect on the levels of SCr, BUN, and blood pressure 
remains uncertain (Spector et al., 2011).  
Most of the studies used accurate measurements of renal function, such a
s SCr,BUN, as well as blood pressure. Although most of the previous studi
es have beenreported on the effects of Pb, there are only a few studies in
which the renal outcome is significantly increased (Li et al., 2008). The 
concern is, however, whether there is 'reverse causality' where U-Pb 
concentration is actually increased as a result of decreased renal function 
in populations with CKD. Due to the fact that the Pb element can cause 
accumulation in the CKD population, accumulative activities also may lead 
to potential nephrotoxicity and may disrupt the physiological function of 
the kidney. Some literature may indicate that the condition may be a 
reverse causation, especially those at a late stage of renal disease 
(Skerving and Bergdahl, 2015). Correlation between U-Pb concentration 
and renal outcome has been widely observed in the general population of 
another developing country. However, most of the previous research 
involves populations of children or lead workers with relatively little 
information on the population of CKD. In addition, no action level for U-Pb 
concentration in CKD population was determined in the previous study. 
While more evidence is needed to explain the mechanisms, a 
comprehensive understanding of the U-Pb concentration in the CKD 
population may help to understand the underlying mechanisms in order 
to discover novel diagnostic, prognosis and treatment approaches to Pb 
nephropathy. 
The main objectives of this research are to study the concentration of U-
Pb in chronic kidney disease patient who was referred to the nephrology 
clinic at Queen Elizabeth Hospital. This study will illustrate the difference 
of U-Pb, SCr, BUN concentration, and diastolic BP between CKD and 
control groups and identify the influences of U-Pb concentration on 
diastolic BP among the participants after controlling the confounding 
factors. Based on previous research, our study hypothesis is that the level 
of SCr, BUN, and BP would also increase with the accumulation of U-Pb in 
the CKD population. 
2. METHODOLOGY AND MATERIAL 
This is a single-center cross-sectional study at the Nephrology Health Care 
Clinic in Queen Elizabeth Hospital, Kota Kinabalu. The hospital caters for 
patients from urban and rural areas around Ranau and Kimanis. Most of 
the patients presented to this clinic are newly diagnosed as CKD and are 
referred here to be assessed by physicians.  They may suffer from different 
stages of decreased renal function, ranging from mild and moderate 
kidney failure (GFR: >90mL/minute/1.73m2) to stage 4 kidney failure 
(GFR: <29 mL/minute/1.73m2) and require the necessary treatment to 
avoid further damage to their kidney. For comparison purposes, patients 
from Papar district Hospital who seek treatment for minor medical 
conditions such as cough, colds or hay fever at the Outpatient department 
and found to have healthy kidney functions were recruited as the control 
group. 
2.1 Ethical approval and consent 
The study protocol was approved by the Medical Research Ethics 
Committee of University Malaysia Sabah (JKEtika 3/17,4) and the 
Malaysian Medical and Research Ethics Committee (MREC), Ministry of 
Health Malaysia (NMRR-17-2625-38629). Furthermore, both study sites 
also received permission from the hospital directors. All respondents were 
required to sign a written informed consent form before enrollment. 
2.2 Patient background 
The sample selection for this study was described in a previous study 
(Abdul et al., 2015). Purposive sampling was used. Patients who visited the 
morning clinic session, aged 18 to 70 years, and agree to participate were 
selected. Pediatrics patients, pregnant women, patients who are 
undergoing RRT therapy (hemodialysis), and those with renal function 
less than 15mL/minute/1.73m² were excluded. 
2.3 Sample size 
The sample size was determined based on the formula N= (4.0 X ∂²) /5² 
suggested by a previous researcher (Snedecor and Cochran, 1980). Using 
the standard deviation for U-Pb concentration (16µg/g) by a researcher, 
total sample size required was 41 (Nina et al., 2011). For quality purposes, 
the number was inflated to 60 samples for each group (60 CKD group, 60 
control groups), making a total of 120 samples required for this study. 
2.4 Sampling method 
A previous researcher described the collection of the urine sample, in 
which 10ml of spot urine sample was collected with the aseptic technique 
using a 250ml acid-cleaned polypropylene bottles containing 0.2ml nitric 
acid 0.2ml (HNO3 69.5%) as preservatives (Johan et al., 2014). The urine 
sample was then immediately transported in cold box to the laboratory of 
the Faculty of Engineering in University Malaysia Sabah immediately 24 
hours. In addition, blood samples were taken from each patient during the 
clinic visit to determine the SCr and BUN levels. The results can be traced 
from the pathological laboratories of both hospitals. 
2.5 Graphite Furnace Atomic Absorption Spectrophotometer 
The instrumentation used to determine the U-Pb concentration is the 
Agilent SpectrAA-400Z Deuterium and Zeeman GFAAS. This instrument is 
associated with a high capability, reliability, and accuracy in analyzing U-
Pb. This optical instrument system improves the graphite furnace power 
supply circuit to ensure high sensitivity. By using a standard hollow 
cathode lamp, the spectrophotometer can be used to analyze Pb element 
in the urine. The calibration curve, sample check, standard check, and 
other QC functions are able to further enhance data reliability. The UMS 
Faculty provided ultrapure water and 1000µg/L Pb stock standard 
solutions (traceable to SRM from NIST Pb (NO₃)₂ in HNO₃ 0.5 mol/l 1000 
mg/l PbCertipur®). The quality control during the experimental 
procedures was described in detail by a previous study (Christine, 2010). 
Nitric acid (HNO3 69.5%, type analytical Use, Cheshire UK) were used for 
urine digestion, and 2% nitric acid was used as an internal standard. All 
polypropylene bottles were thoroughly washed and then soaked 
overnight in nitric acid and rinsed clean with de-ionized water and stored 
in laminar flow hoods before use. To form the 10 μg/mL intermediate Pb 
standard pipet, 1.0 mL stock Pb standard and de-ionized water were 
added by using glass pipettes to a 100mL volumetric flask and the final 
volumes were carefully made up to 100mL. For all calibration standards, 
the concentration of 100 μg/L was prepared by pipetting 1.0 mL 
intermediate standard solution to be diluted to 100mL; similarly, for 200 
and 300 μg/L, 2.0 and 3.0 mL intermediate standard solutions were 
pipetted and diluted to 100mL. The standard solutions must be prepared 
fresh daily. The calibration curve was determined based on standard 
solutions of 10, 20, and 30 µg/dl and the limit of detection for U-Pb is 0.001 
µg/L. A pilot study was carried out to determine the accuracy of the 
instrument analyzer. All working calibration standards for urine sample 
CKD and control group were prepared in the same manner. The result of 
the standards calibration curve indicated a linear value parameter with a 
high correlation coefficient value of >0.97. 
2.6 Measuring of Urinary Creatinine Concentration 
Urinary creatinine was measured with an auto-analyzer instrument to 
correct any large variation in the individual spot urine (Agnes et al., 2012; 
Fumihiro and Shunichi, 2010). The U-Pb concentration was subsequently 
divided by urinary creatinine to reduce the variation of each sample based 
on this formula: (µg/L Pb x 100)/ (mg/dl creatinine) (Analytical 
procedures for the determination of lead in blood and Urine, 2001). 
2.7 Statistical analysis 
Data analyses were performed using SPSS version 21. U-Pb concentration 
was expressed as the mean ± standard deviation and range values at 95% 
confidence intervals. The p-value of less than 0.05 was considered 
significant. Comparison of U-Pb, SCr, BUN, and diastolic BP was carried out 
between the CKD group and the control subjects using the Mann Whitney 
U test and t-test. The correlation of U-Pb concentration with SCr and BUN 
were determined with Spearman Correlation and Pearson correlation for 
diastolic BP. Following that, GLM was performed to determine the effects 
of U-Pb concentration and diastolic BP after controlling for any 
confounding factors. 
3. RESULT 
The individual U-Pb concentration was 0.007µg/g to 37.3µg/g (Figure 1). 
Meanwhile, the mean U-Pb for the CKD group was 4.1µg/g with a standard 
deviation of 7.92. The mean U-Pb for the control group was 3.8µg/g with a 
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standard deviation value of 2.93. The maximum concentration for the CKD 
group was 37.3µg/g as compared to 11.2µg/g for the control group while 
the minimum concentration for the CKD group was 0.05µg/g and 
0.007µg/g for the control group. Table 1 shows a statistically significant 
difference between the CKD and control groups with p-value=0.002 
(<0.05). The median U-Pb concentration in the CKD group was 1.08 (IR 
3.300), which was significantly lower than the control group (median 3.38, 
IR 1.4932). 
 
 
 
Figure 1: The distribution of U-Pb concentration in study groups 
Table 1: The concentration of U-Pb between the CKD group and 
control groups 
Urinary 
Lead 
Mean 
(µg/g) 
Median 
(µg/g) 
Max 
(µg/g) 
Min 
(µg/g) 
Z-
Statisticᵃ 
P 
value 
Study 
groups  
(n = 120) 
3.9±5.95 1.9 37.3 0.007 3.055 0.002ᵇ 
CKD 
group 
 (n = 60) 
 
4.1±7.92 
 
1.1 
 
37.3 
 
0.05 
  
Control 
group  
(n = 60) 
 
3.8±2.93 
 
3.3 
 
11.2 
 
0.007 
  
ᵃMann-WithneyU test was applied 
ᵇsignificant at p<0.05 
Table 2 shows that the mean and SD values of SCr and BUN for the CKD 
group were higher than the control group. The SCr and BUN were 
significantly different between the two groups (p<0.05). The diastolic BP 
in the CKD group was lower than the control group but the two-tailed p-
value was 0.067, indicating no significant difference in diastolic BP 
between CKD and control group. 
Table 2: The levels of SCr, BUN, and Diastolic BP between the CKD 
group and control groups 
Variables CKD (n = 60) Control  
(n = 60) 
z-
statisticᵃ 
t-
statisticᶜ 
P 
value 
SCr 
(μmol/L) 
 
 
BUN 
(mmol/L)  
 
 
Diastolic 
BP 
(mmHg) 
192.3±181.49 
(39-1058) 
 
8.0±6.19 
(6.9-31.7) 
 
82.8±13.63 
(129-61) 
82.4±20.59 
(38.6-135) 
 
4.1±1.22 
(1.4-2.3) 
 
87.3±13.12 
(132-52) 
-5.005 
 
 
-4.455 
 
 
 
 
 
 
 
 
-1.8 (118) 
0.001ᵇ 
 
 
0.001ᵇ 
 
 
0.067ᵈ 
ᵃMann-WithneyU test was applied 
ᵇsignificant at p<0.05 
ᶜIndependent t-test was applied 
ᵈsignificant at p>0.05 
The relationship between U-Pb with SCr, BUN, and diastolic BP for each 
group is shown in Table 3. The results indicated weak correlation (r = -
0.123, -0.101, and -0.127; p<0.05) in the CKD group. Similarly, there was 
also weak correlation between U-Pb with SCr, BUN, and diastolic BP in the 
control group (r = -0.193, 0.127, -0.133). 
Table 3: Correlation of Urinary Lead with SCr, BUN and Diastolic BP in 
Study Groups 
 
Variables 
 
CKD 
(n = 60) 
Urinary 
Lead 
P  value 
 
Control 
(n = 60) 
 
P  value 
SCr (μmol/L) 
 
BUN 
(mmol/L) 
 
Diastolic BP 
(mmHg) 
r=-.123ᵃ 
 
r= -0.101ᵃ 
 
r=-0.127ᵇ 
0.35 
 
0.441 
 
0.33 
r=-.193ᵃ 
 
r=0.127ᵃ 
 
r=-.133ᵇ 
0.14 
 
0.33 
 
31 
ᵃSpearman’s rho correlation was applied 
ᵇPearson correlation was applied 
In this study, the GLM main effect was adjusted for each confounding 
factor. The relationship between U-Pb concentration and diastolic BP after 
adjusted by age, gender, ethnicity, and residential area at univariate 
analysis suggested that p-value for all the confounders were not significant 
(p = 0.195, p = 0.203, p =0.249, p = 0.289 respectively). The findings 
showed that sociodemographic factors did not influence the U-Pb 
concentration of the patients. 
4. DISCUSSIONS 
This study has two significant contributions. First, it is the first study to 
focus on the concentration of U-Pb among the local population in Malaysia. 
Secondly, this is one of the few studies that compare between CKD and 
control groups. This comparison was able to provide evidence for 
researchers to establish the safe concentration level of U-Pb. However, it 
should be noted that the significant values of U-Pb concentration in this 
study were only related to the correction with urinary creatinine. Certain 
comparison is not possible due to the lack of literature and data on the U-
Pb correction with urinary creatinine. 
Closer scrutiny on the U-Pb concentration in this study did not reveal any 
substantial differences in U-Pb concentration mean between the CKD and 
control groups. A previous NHANES study in 2018 showed a higher 
concentration of U-Pb in the control group (2.14µg/g) than the CKD group 
(1.79µg/g) (Jin et al., 2018). By compassion, the U-Pb concentration for the 
healthy group in Korea was slightly higher than the control group in this 
study. However, the U-Pb concentration of all the 120 respondents in this 
study do not exceed the safety level (16 to 60 μg/g) recommended by 
NIOSH (1994) and thus are not regarded as having Pb-toxicity (Lead in 
Blood and Urine, 1994). 
Several possibilities may explain the concentration of U-Pb in both groups. 
Firstly, the U-Pb data in this study suggest that correction for dilution can 
result in different effects for individuals with different kidney function. For 
example, it may have a strong influence on urine samples with low Pb 
concentrations but little or no effects on samples with high Pb 
concentration. This situation may affect those with high urinary 
creatinine, especially CKD patients. Thus, they tend to have a lower 
concentration of U-Pb. Another possible explanation for this inconsistency 
may be related to Pb metabolism. Upon entering the body, Pb will be 
transported out from red blood cell membranes into plasma and is then 
filtered by the kidney throughout the urine within 30 days. However, due 
to impaired renal functions, CKD patients might not be able to excrete it 
rapidly from the kidney (Barbosa et al., 2005). This period of Pb 
accumulation may result in most of the retained Pb being circulated back 
to the bloodstream and stored in the bone (Patrick, 2006). Another 
previous study also reported the fact that decreased kidney function 
compromises its ability in removing Pb, thus resulting in a lower 
concentration of Pb being excreted through urine (Tewodros et al., 2015). 
In addition, this study revealed a statistical difference in the SCr 
concentration of the CKD and control groups, whereby the CKD group had 
a higher concentration of SCr and BUN. This can be caused by the decline 
in renal function to eliminate the waste product of metabolism generated 
from protein breakdown in the body, a phenomenon often presents in CKD 
patients (Chris Higgins, 2016). Interestingly, the findings of this study also 
revealed that the risk of getting higher diastolic BP might not necessarily 
confine to CKD patients. Our study echoed the findings of a previous study 
which reported that the mean value of diastolic BP of the control group in 
this study was comparable to the general population in Malmo, Sweden 
(DBP=87 mmHg, p-value = 0.001) (Angela et al., 2016). 
Mean = 3.993 µg/g 
Std. Dev. = 5.953 
Median = 1.931 µg/g 
N = 120 
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We also identified a weak correlation between U-Pb and SCr in the CKD 
group in this study. By comparison, a scholar indicated a significant 
relationship between U-Pb concentration and SCr (p=0.04) (Ja et al., 
2003). The different results from our study may be attributed to chelation 
therapy (Pizzorno, 2015). Our study also indicated a weak relationship 
between U-Pb with BUN for both CKD and control groups. This finding was 
consistent with a previous study (r = 0.28, p = 0.01). While it may be 
speculated that the association was not significant due to the fact that SCr 
and BUN concentration might not be high enough for detection until the 
very late stage of CKD (Gordon et al., 2009). In our study, not all of the 
participants were in the late stage of CKD. Compared to the control group, 
none of the participants recorded a higher than normal level of SCr and 
BUN of the U-Pb cutoff point. 
While our results revealed higher diastolic BP in the control group 
compared to the CKD group, there was no significant association between 
U-Pb and diastolic BP for both groups. In previous studies, only high 
concentration of Pb may potentially lead to hypertension. The expected 
confounding factor to this finding might be the asymptomatic high blood 
pressure among the control group who were only diagnosed during their 
first clinic visit. The finding showed that sociodemographic factors did not 
influence the concentration of U-Pb. This finding was not in sync with 
another study in which age and other confounding factors were 
consistently observed in populations with high Pb level (Agency for Toxic 
substances and Disease Registry, 2007). 
While the results in this study may explain some of the outcomes of the 
independent variables, the small sample size could have reduced the 
strength of reported associations and insufficient to reveal some of the 
significant associations between the variables. Therefore, further 
validation with a bigger population best in a prospective cohort is needed 
to demonstrate if U-Pb has associated with kidney disease in our society. 
Another limitation of this study is the U-Pb assessment will need further 
validation with the combination of BLL measurements by means of BLL as 
a comparison for better results to be made for both groups. 
5. CONCLUSIONS 
This  study was also unable to prove that high U-Pb is a significant risk of 
developing a high level of SCr, BUN, and diastolic BP as higher 
concentrations of SCr, BUN, and diastolic BP were not associated with a 
higher level of U-Pb concentration in both groups. Furthermore, the U-Pb 
concentration in the study group was still within the normal range based 
on the NIOSH (1994) reference range. Therefore, the correlation between 
U-Pb and renal profile was weak at best. Additionally, there was no 
evidence of Pb accumulation in patients who have yet to start RRT. As 
such, our study also suggested that kidney disease per se does not lead to 
an increase in the body lead stores, thus there is no reverse causation 
which took place in the study group. However, the possibility of Pb 
accumulation may potentially be higher among ESRD patients who have 
started RRT and had low or no urine output. Previous studies presented a 
diverse reference range of U-Pb concentration due to the substantial 
variation in spot urine. Therefore, new correction methods to enhance the 
standard creatinine-correction value simultaneously are needed to 
remove the influence of urine flow rate, especially among the CKD 
population. Further research should look into the impact of other 
variables such as BMI, lifestyle habits such as cigarette smoking and 
alcohol consumption, household income, duration and type of occupation, 
and source of water intake as these are potential risk factors of impaired 
renal functions. 
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ABBREVIATION AND SYMBOL 
ASTDR = Agency for Toxic Substances and Disease Registry 
BLL = Blood Lead Level 
BP = Blood Pressure 
BUN = Blood Urea Nitrogen 
CKD = Chronic Kidney Disease 
FAO = Food and Agriculture Organization 
GLM = General Linear Model 
GFAAS = Graphite Furnace Atomic Absorption Spectrometer 
IR = Interquartile Range 
MREC = Medical Review and Ethics Committee 
NMRR = National Medical Research Register 
Pb = Lead 
RRT = Renal Replacement Therapy 
SCr = Serum Creatinine 
U-Pb = Urinary Lead 
µg/g = Microgram per Gram 
∂ = Standard deviation 
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